Clinical events in patients with low follow-up HDL-C compared with high follow-up HDL-C
| Low HDL-C | High HDL-C | Unadjusted HR (95% CI) | p Value | Adjusted HR* (95% CI) | p Value | |
| Total population (n=2693) | (n=1585) | (n=1108) | ||||
| All-cause death | 45 (2.8) | 16 (1.4) | 2.02 (1.14 to 3.58) | 0.016 | 1.35 (0.59 to 3.08) | 0.471 |
| Cardiac death | 21 (1.3) | 9 (0.8) | 1.66 (0.76 to 3.63) | 0.201 | 1.34 (0.43 to 4.18) | 0.618 |
| MI | 19 (1.2) | 10 (0.9) | 1.34 (0.62 to 2.88) | 0.455 | 1.31 (0.47 to 3.67) | 0.605 |
| Stroke | 28 (1.8) | 18 (1.6) | 1.10 (0.61 to 2.00) | 0.750 | 1.50 (0.61 to 3.68) | 0.382 |
| TLR | 278 (17.5) | 160 (14.4) | 1.22 (1.01 to 1.48) | 0.044 | 1.45 (1.10 to 1.91) | 0.008 |
| TVR | 360 (22.7) | 194 (17.5) | 1.33 (1.11 to 1.58) | 0.002 | 1.46 (1.14 to 1.86) | 0.003 |
| Composite of MACE | 399 (25.2) | 213 (19.2) | 1.34 (1.14 to 1.58) | 0.001 | 1.40 (1.11 to 1.77) | 0.004 |
| Propensity-matched population (n=1980) | (n=990) | (n=990) | ||||
| All-cause death | 15 (1.5) | 11 (1.1) | 1.38 (0.64 to 3.01) | 0.415 | 1.08 (0.28 to 4.14) | 0.915 |
| Cardiac death | 4 (0.4) | 7 (0.7) | 0.57 (0.17 to 1.95) | 0.372 | 0.65 (0.25 to 2.80) | 0.851 |
| MI | 11 (1.1) | 10 (1.0) | 1.09 (0.46 to 2.58) | 0.837 | 0.85 (0.23 to 3.11) | 0.805 |
| Stroke | 18 (1.8) | 18 (1.8) | 0.99 (0.52 to 1.91) | 0.986 | 0.59 (0.22 to 1.60) | 0.298 |
| TLR | 186 (18.8) | 136 (13.7) | 1.37 (1.10 to 1.71) | 0.005 | 1.64 (1.22 to 2.19) | 0.001 |
| TVR | 237 (23.9) | 168 (17.0) | 1.44 (1.18 to 1.75) | <0.001 | 1.65 (1.27 to 2.13) | <0.001 |
| Composite of MACE | 248 (25.1) | 183 (18.5) | 1.38 (1.14 to 1.67) | 0.001 | 1.55 (1.21 to 2.00) | 0.001 |
↵* Adjusted covariates included age, sex, hypertension, diabetes mellitus, chronic renal disease, current smoker, acute coronary syndrome, ejection fraction, baseline high-density lipoprotein (HDL), baseline low-density lipoprotein (LDL), baseline triglycerides (TG), baseline high sensitivity C reactive protein (hs-CRP), follow-up LDL, follow-up TG, follow-up hs-CRP, total stent length, mean stent diameter, number of stent, number of B2/C lesions.
HDL-C, high-density lipoprotein cholesterol; MACE, major adverse cardiac events; MI, myocardial infarction; TLR, target lesion revascularisation; TVR, target vessel revascularisation.